Diffusion Pharmaceuticals
2020 Avon Court, Suite 4
Charlottesville
Virginia
22902
United States
Tel: 434-220-0718
Fax: 434-220-0722
Website: http://www.diffusionpharma.com/
130 articles with Diffusion Pharmaceuticals
-
Diffusion Pharmaceuticals Begins Phase III Clinical Trial With TSC in Glioblastoma Multiforme
12/27/2017
The trial will screen 300 patients and enroll 264 in an effort to ensure that results from 236 patients will be available for analysis.
-
Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule
11/20/2017
The Company today announced that it has received notice from Nasdaq stating that the Company complies with the Nasdaq Capital Market Listing Rules requiring minimum stockholders’ equity of $2.5 million.
-
Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
11/13/2017
We had cash, cash equivalents and a certificate of deposit totaling $11.2 million as of September 30, 2017.
-
Diffusion Pharma Receives Final FDA Protocol Guidance for Phase III Clinical Trial with TSC in Pa...
10/17/2017
The company expects to begin trial by year-end. -
Diffusion Pharma Names William Hornung Chief Business Officer
8/23/2017
-
Diffusion Pharma Reports Second Quarter 2017 Financial Results And Provides Business Update
8/15/2017
-
Diffusion Pharma Selects Contract Research Organization For Phase III Clinical Trial Of Lead Compound TSC For Inoperable GBM Brain Cancer
7/31/2017
-
Diffusion Pharma Achieves Drug Production Milestone For Planned Phase III Clinical Trial In Inoperable GBM Brain Cancer
7/20/2017
-
Diffusion Pharma Appoints Dr. Robert Ruffolo To Board Of Directors
7/6/2017
-
Diffusion Pharma Provides Corporate Highlights And Reports Financial First Quarter 2017 Results
5/16/2017
-
Diffusion Pharma Awarded U.S. Patent For TSC As Therapeutic In Five Hypoxia-Related Indications
4/4/2017
-
Diffusion Pharma Announces Closing Of Oversubscribed Private Placement
4/3/2017
-
Diffusion Pharma Provides Corporate Highlights And Reports 2016 Financial Results
3/31/2017
-
Diffusion Pharma’ TSC Phase I/II Glioblastoma Multiforme Clinical Trial Results Published In February 2017 Edition Of Journal Of Neurosurgery
2/8/2017
-
Diffusion Pharma Files Definitive Proxy Statement For Upcoming Special Meeting Of Stockholders
12/12/2016
-
Diffusion Pharma Provides Corporate Highlights and Reports Financial Third Quarter 2016 Results
11/14/2016
-
Diffusion Pharma Announces Uplisting To NASDAQ Capital Market
11/8/2016
-
Diffusion Pharma Establishes Scientific Advisory Board
9/29/2016
-
Diffusion Pharma Successfully Completes Animal Toxicity Studies In Preparation For Phase III Pivotal Trial Of TSC In New Diagnosed Glioblastoma Patients
9/19/2016
-
Diffusion Pharma To Present At 18th Annual Rodman & Renshaw Global Investment Conference
9/9/2016